| Riverside University Health System | |
|
26520 Cactus Ave Moreno Valley CA 92555-3927 | |
| (951) 486-4000 | |
| (951) 486-4435 |
| Full Name | Riverside University Health System |
|---|---|
| Speciality | Clinic/Center |
| Location | 26520 Cactus Ave, Moreno Valley, California |
| Authorized Official Name and Position | Gene Reyes (EXECUTIVE DIRECTOR OF REVENUE CYCLE) |
| Authorized Official Contact | 9514864421 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Riverside University Health System 26520 Cactus Ave Moreno Valley CA 92555-3927 Ph: (951) 486-4000 | Riverside University Health System 26520 Cactus Ave Moreno Valley CA 92555-3927 Ph: (951) 486-4000 |
| NPI Number | 1003293911 |
|---|---|
| Provider Enumeration Date | 04/29/2015 |
| Last Update Date | 05/13/2021 |
| Medicare PECOS PAC ID | 6507754488 |
|---|---|
| Medicare Enrollment ID | O20160707000380 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003293911 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
| Provider Name | Adolfo Aguilera |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477609808 PECOS PAC ID: 1658318837 Enrollment ID: I20050408000968 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Faheem Mohammed Jukaku |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518072230 PECOS PAC ID: 9931146784 Enrollment ID: I20050413000258 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Priya S Victor |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366590382 PECOS PAC ID: 4082707179 Enrollment ID: I20070905000748 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Geoffrey W Leung |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831261155 PECOS PAC ID: 7719069137 Enrollment ID: I20080124000247 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Sharon Jack |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831348663 PECOS PAC ID: 5890843767 Enrollment ID: I20090502000033 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Mahbuba Khan |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841524824 PECOS PAC ID: 5597937268 Enrollment ID: I20111003000283 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Khaing Myint |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518977511 PECOS PAC ID: 2264628049 Enrollment ID: I20160815000028 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Wael Hamade |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295924710 PECOS PAC ID: 7113094723 Enrollment ID: I20160818000947 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Purnima Verma Gandhi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790070852 PECOS PAC ID: 3173818937 Enrollment ID: I20160818002127 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Shunling Tsang |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1497052443 PECOS PAC ID: 4880989318 Enrollment ID: I20160823002731 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Parastou Farhadian |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538496419 PECOS PAC ID: 8224323621 Enrollment ID: I20160824001987 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Amar Dave |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336588623 PECOS PAC ID: 8921368887 Enrollment ID: I20180214001464 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
| Provider Name | Moazzum Nabeel Bajwa |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780062869 PECOS PAC ID: 9931464294 Enrollment ID: I20180607002002 |
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
News Archive
Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.
A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.
Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
› Verified 7 days ago
Antonio A. Tan, Md, Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12980 Frederick St, Suite D, Moreno Valley, CA 92553 Phone: 951-485-2744 Fax: 951-485-2749 | |
Dong S. Kim, M.d., Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11441 Heacock St, Ste. F, Moreno Valley, CA 92557 Phone: 951-243-8000 Fax: 951-243-9707 | |
Planned Parenthood Pacific Southwest Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12900 Frederick St Ste C, Moreno Valley, CA 92553 Phone: 951-222-3101 | |
Joel A Pengson, Md, A Medical Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 23180 Hemlock Ave, Moreno Valley, CA 92557 Phone: 951-243-6460 | |
John Liquete Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 14114 Business Center Dr, Suite D, Moreno Valley, CA 92553 Phone: 951-697-1150 | |
Yogendra B Patel,md,inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12980 Frederick St, Suite J, Moreno Valley, CA 92553 Phone: 951-924-9300 Fax: 951-485-0240 |